Overview

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Status:
Not yet recruiting
Trial end date:
2026-05-23
Target enrollment:
Participant gender:
Summary
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of Vienna
Collaborator:
Daiichi Sankyo, Inc.